Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort Study

Inclusion Criteria: * Patients of both sexes aged 18 to 75 years who are citizens of the Republic of Kazakhstan; * An established diagnosis of CGD (chronic viral hepatitis B with the delta agent); * Patients who have contraindications to taking peg-INF-alpha2a and/or have failed treatment with peg-INF-alpha2a; * Compensated liver disease ≤ CPT A (6 points); * Patients without severe concomitant diseases; * Patients who do not receive other adjuvant therapy (metabolic therapy drugs, essential phospholipids, ursodeoxycholic acid, glycyrrhizic acid, ademetionine and others); * Patients who voluntarily signed the informed consent form. Exclusion Criteria: * Patients taking COC for more than 4 weeks before inclusion in the study; * Patients with contraindications to the COC; * Decompensated liver disease severity class \> CPT A6; * Patients taking peg-IFN-alpha 2a; * Alcohol abuse according to the AUDIT-c questionnaire; * Pregnancy and lactation; * Patients with coinfection with HIV, HCV; * GFR ≤ 15 ml/min/1.73 m2; * Exclude patients with significant biochemical activity (ALT, AST more than 10 ULN) and total bilirubin more than 2 norms; * Patients with other causes of liver damage; * Drug addict people; * Malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than 5 times or more; * Patient takes part in an interventional clinical trial.